Skip to main content
Fig. 4 | Cell & Bioscience

Fig. 4

From: MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer

Fig. 4

STING downregulation leads to PARPi resistance in TNBC. A Western blotting analysis for STING-GFP, STING, and β-actin (loading control) comparing STING-OV and empty vector (CTRL) in MDA-MB-436, HCC1395, and HCC1937 cell lines. B–D Drug sensitivity assays comparing STING-OV and empty vector (CTRL) in MDA-MB-436 (C), HCC1395 (D), and HCC1937 (E), treated with different concentrations of olaparib (Two-way ANOVA and Sidak’s multiple comparisons test). E Western blotting analysis for STING and β-actin (loading control) comparing si-STING and the respective si-CTRL in three BRCA mt TNBC cell lines MDA-MB-436, HCC1395, and HCC1937. F–H Drug sensitivity assays comparing si-STING and si-CTRL in MDA-MB-436 (F), HCC1395 (G), and HCC1937 (H) cell lines, treated with different concentrations of olaparib (Two-way ANOVA and Sidak’s multiple comparisons test). *p < 0.05, **p < 0.01, ***p < 0.001. Cell viability assays were performed in triplicates

Back to article page